Press Release
We forward herewith press note on Out Licensing Deal with US Based Generics Company.29-05-2017
29-05-2017
Outcome of Board Meeting
We wish to inform you that the Board of Directors of the company at their meeting held today have approved the Scheme of Amalgamation of Lyka Healthcare Limited (Transferor Company) being the wholly owned subsidiary with Lyka Labs Limited (Transferee Company) w.e.f 1st April, 2017 as per the terms and conditions mentioned in the Scheme of Amalgamation (the Scheme) subject to requisite approvals.29-05-2017
1. Audited Standalone Financial Results For The Fourth Quarter And Financial Year Ended 31St March, 2017. 2. Audited Consolidated Financial Results For The Fourth Quarter And Financial Year Ended 31St March,2017. 3. Auditors Report.
With respect to above, we wish to inform you that the Board of Directors at their meeting held today have adopted the Audited Standalone Financial Results for the Fourth Quarter and Financial Year ended 31st March, 2017 and Audited Consolidated Financial Results for the Fourth Quarter and Financial Year ended 31st March, 2017. (For more details kindly refer Corporate Announcements on www.bseindia.com). We forward herewith copy of the Audited...29-05-2017
1. Audited Standalone Financial Results For The Fourth Quarter And Financial Year Ended 31St March, 2017. 2. Audited Consolidated Financial Results For The Fourth Quarter And Financial Year Ended 31St March,2017. 3. Auditors Report.
With respect to above, we wish to inform you that the Board of Directors at their meeting held today have adopted the Audited Standalone Financial Results for the Fourth Quarter and Financial Year ended 31st March, 2017 and Audited Consolidated Financial Results for the Fourth Quarter and Financial Year ended 31st March, 2017. (For more details kindly refer Corporate Announcements on www.bseindia.com). We forward herewith copy of the Audited...29-05-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra I Gandhi24-05-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra I Gandhi (HUF)17-05-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra I Gandhi (HUF)17-05-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra Ishwarlal Gandhi15-05-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narendra I Gandhi (HUF)27-04-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nehal Narendra Gandhi27-04-2017